Email This Release
Galderma, Nestlé Skin Health’s Medical Solutions Business, Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words: